What are the treatment options for Meige (Meiges) syndrome?

Treatment of Meige Syndrome

Botulinum toxin type A injections into the eyelid and facial musculature represent the first-line treatment for Meige syndrome, with over 72% of patients continuing this therapy long-term due to its superior efficacy and safety profile 1.

Primary Treatment Approach

Botulinum Toxin Injections (First-Line)

• Local injections of botulinum toxin type A into affected muscles (eyelids, perioral, jaw) provide the most consistent relief
• In a long-term study of 239 patients followed over 11 years, 202 patients (72.1%) continued with botulinum toxin as their preferred treatment 1
• Approximately 2.2% of patients experienced apparent disease remission after injection therapy 1
• This should be your initial treatment for all patients with Meige syndrome

Adjunctive Oral Medications

When botulinum toxin alone is insufficient, consider adding:

• Minor tranquilizers/benzodiazepines - shown to be effective in combination therapy 1, 2
• Baclofen (muscle relaxant) 2
• Carbidopa-levodopa 2
• Anticholinergic drugs 2
• Haloperidol (dopamine receptor antagonist) - successfully treated 1 patient who refused botulinum toxin 1

Surgical Options for Refractory Cases

When medical management fails (refractory to botulinum toxin and oral medications), escalate to surgical intervention:

Deep Brain Stimulation (Preferred Surgical Option)

Bilateral subthalamic nucleus (STN) DBS is the optimal surgical target for medically refractory Meige syndrome, particularly when considering both motor outcomes and neuropsychiatric benefits 3.

Target Selection:

• STN-DBS: Provides 61% improvement in movement scores and 57% improvement in disability scores at long-term follow-up (mean 62 months) 3

  • Superior for patients with depression/anxiety: Significantly greater improvements in Hamilton depression scores (-3.38 vs -0.33 points) and anxiety scores (-3.43 vs -0.19 points) compared to GPi 4
  • Optimal lead placement: dorsolateral sensorimotor subregion of STN 3

• GPi-DBS: Equivalent motor outcomes to STN but less benefit for mood symptoms 4

  • Consider if patient has no significant depression/anxiety
  • Both targets show similar improvements in quality of life and sleep 4

Prognostic Factors for DBS Success:

Early intervention is critical - the following predict poorer outcomes 3:

• Longer disease duration before surgery (worse outcomes)
• Older age at time of surgery (worse outcomes)
• Smaller volume of tissue activated within sensorimotor STN (worse outcomes)

Therefore, refer patients for DBS evaluation early when medical management fails, rather than waiting years.

Alternative Surgical Procedures

CT-Guided Radiofrequency Ablation of Facial Nerve

• Partial ablation at the stylomastoid foramen provides immediate cessation of spasms 5
• Lower cost and risk compared to DBS, but:
  • Causes temporary mild facial paralysis (resolves in ~3 months) 5
  • Recurrence rates: 15.5% unilateral, 5.2% bilateral within 6-22 months 5
• Consider for patients who cannot afford or tolerate DBS

Orbicularis Muscle Extirpative Surgery

• Only 1.3% of patients achieved lasting relief without additional treatment 1
• Reserve as last-line option when other treatments fail

Alternative/Complementary Therapy

Acupuncture

• Case report shows significant symptom improvement after 4 weeks 6
• May serve as adjunctive or salvage therapy, but evidence is limited to case reports
• Consider for patients seeking non-invasive options or as complement to primary treatments

Treatment Algorithm

1. Start with botulinum toxin type A injections - repeat every 3-4 months as needed
2. Add oral medications if botulinum toxin provides incomplete relief (benzodiazepines, baclofen, carbidopa-levodopa)
3. Refer for DBS evaluation early when symptoms remain refractory to combined medical therapy
   • Choose STN-DBS as first choice, especially if depression/anxiety present
   • Choose GPi-DBS if no mood symptoms and patient/surgeon preference
4. Consider CT-guided radiofrequency ablation if DBS unavailable or unaffordable
5. Reserve muscle surgery for rare cases unresponsive to all other options

Critical Pitfalls to Avoid

• Delaying DBS referral: Longer disease duration and older age at surgery predict worse outcomes 3 - refer early when medical management fails
• Inadequate botulinum toxin trial: Ensure proper dosing and injection technique before declaring treatment failure
• Ignoring neuropsychiatric comorbidities: Depression and anxiety are common; STN target selection can address both motor and mood symptoms 4
• Suboptimal DBS targeting: Ensure leads are placed in dorsolateral sensorimotor STN for best results 3